U.S. Positron Emission Tomography Devices Market Size, Share & Forecast 2026–2032

ID: MR-11903 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: PET Devices
  • ✓Market Size 2024: USD 1.12 billion
  • ✓Market Size 2032: USD 1.84 billion
  • ✓CAGR: 6.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Isotope Logistics Set Capacity: Fluorine-18 decays within roughly 110 minutes, so every U.S. PET scan depends on a cyclotron within a short courier radius. PETNET Solutions, a Siemens Healthineers unit, controls one of the largest national tracer distribution networks, giving it throughput leverage that scanner-only competitors lack.
FINDING 02
Replacement Cycles Drive Orders: Most observers credit PSMA tracer approvals with driving scanner growth, but hospital replacement cycles generate most U.S. unit orders. GE HealthCare and Siemens Healthineers report that installed-base upgrades, not greenfield sites, now account for the majority of their North American PET revenue.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Supply Contracts Early: Hospital procurement directors should secure fixed-price PET/CT service and tracer supply contracts before the first quarter of 2026, because pending Section 232 medical device measures will raise imported component costs. Pair each scanner with a radiopharmacy within 100 miles to protect delivery windows.

The United States' Role in the Global PET Device Supply Chain

The United States operates the largest installed base of positron emission tomography systems in the world, with more than 2,000 units in clinical use, yet it remains a net importer of finished scanners and subcomponents. Final assembly is concentrated in two domestic plants: Siemens Healthineers builds PET/CT systems in Knoxville, Tennessee, and GE HealthCare assembles its PET/CT line in Waukesha, Wisconsin. Scintillation crystals, photomultiplier tubes and detector electronics still arrive from Germany, Japan and the Netherlands, placing the country at the end of long, precision-dependent supply lanes.

The higher-value node sits in radiopharmaceutical production rather than hardware. Fludeoxyglucose F-18 is produced across hundreds of cyclotron-equipped sites, while PSMA imaging agents such as Pylarify, marketed by Lantheus, are manufactured domestically under FDA-approved processes. Gallium-68 generator feedstock and germanium-68 remain thin supply points, sourced from a handful of global producers including Russian-origin material, which exposes the chain to sanctions and single-source disruption.

Growth Drivers for PET Devices in the United States

Two demand catalysts are reshaping trade flows. FDA approvals of Pylarify, Illuccix and Locametz between 2021 and 2022 created PSMA imaging demand that requires dedicated PET/CT capacity, generator-produced gallium-68 and cyclotron-produced fluorine-18. CMS removed its coverage-with-evidence-development restriction on amyloid PET in 2023, opening Medicare volumes for Alzheimer's diagnostics and lifting utilization in community hospitals that previously lacked scanner access.

The third driver is domestic substitution. Siemens Healthineers and GE HealthCare have expanded U.S. assembly footprints to reduce tariff exposure on finished imports, shifting value toward the Tennessee and Wisconsin plants. United Imaging's total-body uEXPLORER platform has entered U.S. academic procurement, pressing incumbents to localize detector production and service networks to defend share in research-intensive hospitals.

Supply Chain Risks and Trade Barriers

Radioisotope dependency is the most acute vulnerability. Germanium-68 feedstock is concentrated among a few suppliers, and any interruption halts gallium-68 generator output that supports PSMA imaging volumes nationwide. Fluorine-18 logistics add a second constraint, because short half-lives force cyclotron siting within roughly 100 miles of each scanner, leaving rural hospitals and independent imaging centers with limited sourcing options.

Trade policy exposure is rising. Detector components and electronics from China face Section 301 duties, and the Section 232 inquiry into medical devices threatens to widen cost pressure across imported subassemblies. Euro-denominated component contracts with German suppliers add currency risk, while Medicare physician fee schedule constraints limit hospitals' ability to pass higher equipment costs through to reimbursement rates.

Trade and Investment Opportunities in the United States

Mobile and satellite cyclotron networks represent the clearest commercial gap. PETNET Solutions and independent radiopharmacy operators such as Jubilant Radiopharmacies can extend tracer distribution into secondary markets where scanner installations are growing faster than tracer access. Investors backing regional cyclotron-and-radiopharmacy hubs near existing PET/CT clusters in Tennessee, Wisconsin and the Mid-Atlantic would capture recurring isotope revenue tied to scanner utilization.

Import substitution in components offers a second opening. Domestic production of LYSO scintillation crystals, photodetector modules and detector electronics would reduce exposure to Section 301 duties and German currency swings. Foreign direct investment into these subassembly lines, combined with USMCA-compliant sourcing from Mexican electronics plants, would give scanner makers tariff-resilient supply and a stronger bid position in federal and academic procurement.

Market at a Glance

MetricValue
Market Size 2024USD 1.12 billion
Market Size 2032USD 1.84 billion
Growth Rate (CAGR)6.4%
Most Critical Decision FactorSecure isotope supply within 100-mile cyclotron radius
Largest RegionSouth Region
Competitive StructureOligopoly led by three scanner OEMs

Leading Market Participants

  • GE HealthCare
  • Siemens Healthineers
  • Philips
  • Canon Medical Systems USA
  • United Imaging Healthcare
  • PETNET Solutions
  • Lantheus
  • Cardinal Health
  • Jubilant Radiopharmacies
  • SOFIE

Regulatory and Trade Policy Environment

PET scanners are regulated by the FDA through the 510(k) pathway, while PET radiopharmaceuticals require New Drug Application approval and manufacturing under current good manufacturing practice. The Nuclear Regulatory Commission and Agreement States license byproduct material used in cyclotron and generator operations. Most imaging equipment enters duty-free under the Nairobi Protocol, but Section 301 duties apply to Chinese-origin goods, and USMCA governs component flows from Canada and Mexico.

Investment policy remains open to foreign manufacturers, though national security reviews under CFIUS apply to acquisitions involving radioisotope production assets. Medicare coverage determinations, including the 2023 amyloid PET decision, shape demand more directly than trade rules do. Hospital purchasing groups increasingly require domestic service coverage, which favors manufacturers with nationwide field engineering networks.

U.S. PET Devices Supply Chain Outlook to 2032

The U.S. supply chain will shift from centralized scanner imports toward localized assembly and distributed tracer production through 2032. Expanded PET/CT capacity in Tennessee and Wisconsin will reduce reliance on finished imports, while total-body systems will require new detector supply from domestic or USMCA-partner sources. Tracer production will decentralize as satellite cyclotrons spread into community hospitals.

Technology will reshape comparative advantage. AI-driven image reconstruction reduces the radiotracer dose required per scan, lowering isotope demand per procedure and easing cyclotron throughput constraints. Manufacturers that combine dose-reduction software with localized detector production will hold a durable cost advantage over import-dependent competitors as Medicare reimbursement tightens.

Frequently Asked Questions

Domestic assembly covers final PET/CT systems, but scintillation crystals, photomultiplier tubes and detector electronics still arrive from Germany, Japan and the Netherlands. Specialized precision manufacturing in those countries keeps component imports necessary.
Fluorine-18 decays within about 110 minutes, so cyclotrons must sit within roughly 100 miles of each scanner. Rural hospitals and independent centers face the greatest sourcing constraints as a result.
Section 301 duties apply to Chinese-origin components, and the Section 232 medical device inquiry adds further cost exposure. Manufacturers respond by localizing assembly and detector production.
The USMCA governs duty treatment and rules of origin for components moving across North American borders. Compliant sourcing from Mexican electronics plants supports tariff-resilient supply.
Gallium-68 generators depend on germanium-68 feedstock from a small number of global producers, including Russian-origin material. Any interruption directly limits PSMA imaging volumes nationwide.

Market Segmentation

By Device Type
  • PET/CT Systems
  • PET/MRI Systems
  • Standalone PET Scanners
  • Total-Body PET Systems
By End User
  • Hospitals
  • Academic Medical Centers
  • Ambulatory Imaging Centers
  • Independent Diagnostic Imaging Centers
  • Veterans Affairs Facilities
By Clinical Application
  • Oncology
  • Neurology
  • Cardiology
  • Infection and Inflammation

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 United States PET Devices - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Device Type Insights
4.1 PET/CT Systems
4.2 PET/MRI Systems
4.3 Standalone PET Scanners
4.4 Total-Body PET Systems
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Academic Medical Centers
5.3 Ambulatory Imaging Centers
5.4 Independent Diagnostic Imaging Centers
5.5 Others
Chapter 06 Clinical Application Insights
6.1 Oncology
6.2 Neurology
6.3 Cardiology
6.4 Infection and Inflammation
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 GE HealthCare
7.2.2 Siemens Healthineers
7.2.3 Philips
7.2.4 Canon Medical Systems USA
7.2.5 United Imaging Healthcare
7.2.6 PETNET Solutions
7.2.7 Lantheus
7.2.8 Cardinal Health
7.2.9 Jubilant Radiopharmacies
7.2.10 SOFIE
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.